FDA Approves Impax's Generic Corzide

Impax Laboratories announced that the FDA has granted final approval to its abbreviated new drug applications for generic Corzide 40 mg/5 mg and 80 mg/5 mg. The company will begin marketing the products through its Global Pharmaceuticals division in the near future.

Corzide (nadolol/bendroflumethiazide), marketed by Monarch Pharmaceuticals, a wholly owned subsidiary of King Pharmaceuticals, is for the treatment of hypertension and had sales of approximately $5.5 million in the 12 months ending Feb. 28, according to Wolters Kluwer Health data cited by the company.

"This is our first approval in 2007, and we are very pleased to add generic Corzide to the growing portfolio of products our Global Pharmaceuticals division offers to patients," Larry Hsu, president and CEO of Impax, said.